Skip to main content

Table 1 Patients Characteristics (n = 95).

From: Activity and side effects of imatinib in patients with gastrointestinal stromal tumors: data from a german multicenter trial

Age (yrs)  
   Median 59
   Range 18-80
Sex (No)  
   Male 56
   Female 39
ECOG (No)  
   Grade 0 36
   Grade 1 40
   Grade 2 17
   Grade 3 2
Time since initial diagnosis (days)  
   Median 180
   Range 0-6141
Disease Status (%)  
   Recurrence/Progression 62
Site of tumor (%)  
   Stomach 33
   Liver 28
   Small intestine 23
   Peritoneum 5
   Rectum 5
   Colon 4
   Esophagus 1
   Pancreas 1